These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23122665)

  • 1. Strengthening evidence for active surveillance for prostate cancer.
    Klotz L
    Eur Urol; 2013 Jan; 63(1):108-10. PubMed ID: 23122665
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
    Hongo F; Okihara K; Kitamura K; Fujihara A; Yamada Y; Shiraishi T; Konishi E; Ukimura O
    Int J Urol; 2019 Aug; 26(8):827-832. PubMed ID: 31183899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pragmatic Approach to Prostate Cancer Screening.
    Tosoian JJ; Penson DF; Chinnaiyan AM
    JAMA; 2024 May; 331(17):1448-1450. PubMed ID: 38581253
    [No Abstract]   [Full Text] [Related]  

  • 4. Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
    Chen K; Murphy D; Lawrentschuk N
    J Urol; 2022 Feb; 207(2):265-267. PubMed ID: 34788547
    [No Abstract]   [Full Text] [Related]  

  • 5. [Presence of prostate cancer, but absence of active treatment].
    Blanker MH; Bangma CH
    Ned Tijdschr Geneeskd; 2019 May; 163():. PubMed ID: 31187962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
    Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience?
    Baum M
    Eur Urol; 2013 Oct; 64(4):540-1. PubMed ID: 23768633
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
    Roobol MJ; Kranse R; Bangma CH; Otto SJ; van der Kwast TH; Bokhorst LP; de Koning HJ; Schröder FH
    Eur Urol; 2013 Oct; 64(4):541-3. PubMed ID: 23816273
    [No Abstract]   [Full Text] [Related]  

  • 10. Active surveillance: current and future directions.
    Klotz L
    Curr Opin Urol; 2013 May; 23(3):237-8. PubMed ID: 23548977
    [No Abstract]   [Full Text] [Related]  

  • 11. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Surveillance: Pathologic and Clinical Variables Associated with Outcome.
    Pomerantz M
    Surg Pathol Clin; 2015 Dec; 8(4):581-5. PubMed ID: 26612216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.
    Whitson JM; Porten SP; Carroll PR
    Nat Rev Urol; 2011 Mar; 8(3):124-5. PubMed ID: 21304508
    [No Abstract]   [Full Text] [Related]  

  • 14. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
    J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healing or harming: the prostate cancer dichotomy.
    Zarrabi A; Mark S
    N Z Med J; 2020 Oct; 133(1523):12-15. PubMed ID: 33032299
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate-specific antigen-based screening for prostate cancer: the irony of it all.
    Carter HB
    Eur Urol; 2013 Nov; 64(5):710-1; discussion 711-2. PubMed ID: 23773555
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer options expand beyond the PSA.
    Clin Resour Manag; 2002 May; 3(5):65-8. PubMed ID: 12048767
    [No Abstract]   [Full Text] [Related]  

  • 20. Valentine's Day PSA.
    Dasgupta P
    BJU Int; 2014 Feb; 113(2):177. PubMed ID: 24712694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.